Literature DB >> 1436092

A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors.

D Oksenberg1, S A Marsters, B F O'Dowd, H Jin, S Havlik, S J Peroutka, A Ashkenazi.   

Abstract

Neuropsychiatric disorders such as anxiety, depression, migraine, vasospasm and epilepsy may involve different subtypes of the 5-hydroxytryptamine (5-HT) receptor. The 1B subtype, which has a unique pharmacology, was first identified in rodent brain. But a similar receptor could not be detected in human brain, suggesting the absence in man of a receptor with equivalent function. Recently a human receptor gene was isolated (designated 5-HT1B receptor, 5-HT1D beta receptor, or S12 receptor) which shares 93% identity of the deduced protein sequence with rodent 5-HT1B receptors. Although this receptor is identical to rodent 5-HT1B receptors in binding to 5-HT, it differs profoundly in binding to many drugs. Here we show that replacement of a single amino acid in the human receptor (threonine at residue 355) with a corresponding asparagine found in rodent 5-HT1B receptors renders the pharmacology of the receptors essentially identical. This demonstrates that the human gene does indeed encode a 1B receptor, which is likely to have the same biological functions as the rodent 5-HT1B receptor. In addition, these findings show that minute sequence differences between homologues of the same receptor from different species can cause large pharmacological variation. Thus, drug-receptor interactions should not be extrapolated from animal to human species without verification.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436092     DOI: 10.1038/360161a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  40 in total

1.  Molecular cloning, pharmacological properties and tissue distribution of the porcine 5-HT(1B) receptor.

Authors:  P Bhalla; H S Sharma; X Ma; T Wurch; P J Pauwels; P R Saxena
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  An evaluation of the effect of NAS-181, a new selective 5-HT(1B) receptor antagonist, on extracellular 5-HT levels in rat frontal cortex.

Authors:  Lotte de Groote; André A Klompmakers; Berend Olivier; Herman G M Westenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-24       Impact factor: 3.000

3.  Structural requirements of bitter taste receptor activation.

Authors:  Anne Brockhoff; Maik Behrens; Masha Y Niv; Wolfgang Meyerhof
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

4.  Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369.

Authors:  Katarina Varnäs; Svante Nyberg; Per Karlsson; M Edward Pierson; Matts Kågedal; Zsolt Cselényi; Dennis McCarthy; Alan Xiao; Minli Zhang; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2011-01-15       Impact factor: 4.530

5.  Molecular Architecture of G Protein-Coupled Receptors.

Authors:  A Michiel van Rhee; Kenneth A Jacobson
Journal:  Drug Dev Res       Date:  1996-01-01       Impact factor: 4.360

6.  Differences in ligand binding profiles between cloned rabbit and human 5-HT1D alpha and 5-HT1D beta receptors: ketanserin and methiothepin distinguish rabbit 5-HT1D receptor subtypes.

Authors:  J A Bard; S A Kucharewicz; J M Zgombick; R L Weinshank; T A Branchek; M L Cohen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

7.  Modelling the P2Y purinoceptor using rhodopsin as template.

Authors:  A M Van Rhee; B Fischer; P J Van Galen; K A Jacobson
Journal:  Drug Des Discov       Date:  1995-11

8.  Contractile 5-HT1B receptors in human cerebral arteries: pharmacological characterization and localization with immunocytochemistry.

Authors:  T Nilsson; J Longmore; D Shaw; I J Olesen; L Edvinsson
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

9.  Comparative pharmacology of recombinant rat AT1A, AT1B and human AT1 receptors expressed by transfected COS-M6 cells.

Authors:  A J Balmforth; S E Bryson; A J Aylett; P Warburton; S G Ball; K T Pun; D Middlemiss; G M Drew
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

10.  Construction of a novel bifunctional biogenic amine receptor by two point mutations of the H2-histamine receptor.

Authors:  J DelValle; I Gantz; L Wang; Y J Guo; G Munzert; T Tashiro; Y Konda; T Yamada
Journal:  Mol Med       Date:  1995-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.